{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T02:49:31Z","timestamp":1648522171330},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00393-016-0131-1","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T04:50:52Z","timestamp":1468471852000},"page":"537-541","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inflammasom und Gicht"],"prefix":"10.1007","volume":"75","author":[{"given":"M.","family":"Aringer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-K.","family":"Tausche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"issue":"7","key":"131_CR1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21(7):677\u2013687","journal-title":"Nat Med"},{"issue":"1","key":"131_CR2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/imr.12283","volume":"265","author":"J Chavarria-Smith","year":"2015","unstructured":"Chavarria-Smith J, Vance RE (2015) The NLRP1 inflammasomes. Immunol Rev 265(1):22\u201334","journal-title":"Immunol Rev"},{"key":"131_CR3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coi.2015.01.010","volume":"32","author":"RE Vance","year":"2015","unstructured":"Vance RE (2015) The NAIP\/NLRC4 inflammasomes. Curr Opin Immunol 32:84\u201389","journal-title":"Curr Opin Immunol"},{"issue":"7427","key":"131_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature11588","volume":"492","author":"GS Lee","year":"2012","unstructured":"Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB et al (2012) The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492(7427):123\u2013127","journal-title":"Nature"},{"issue":"6","key":"131_CR5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00393-015-1572-7","volume":"74","author":"G Horneff","year":"2015","unstructured":"Horneff G (2015) Autoinflammatory syndromes in childhood. Z Rheumatol 74(6):511\u2013524","journal-title":"Z Rheumatol"},{"issue":"3","key":"131_CR6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29(3):301\u2013305","journal-title":"Nat Genet"},{"issue":"1","key":"131_CR7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/341357","volume":"71","author":"J Feldmann","year":"2002","unstructured":"Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E et\u00a0al (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J\u00a0Hum Genet 71(1):198\u2013203","journal-title":"Am J\u00a0Hum Genet"},{"issue":"12","key":"131_CR8","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.10688","volume":"46","author":"I Aksentijevich","year":"2002","unstructured":"Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR et al (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46(12):3340\u20133348","journal-title":"Arthritis Rheum"},{"issue":"5","key":"131_CR9","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1073\/pnas.0708616105","volume":"105","author":"I Jeru","year":"2008","unstructured":"Jeru I, Duquesnoy P, Fernandes-Alnemri T, Cochet E, Yu JW, Lackmy-Port-Lis M et al (2008) Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 105(5):1614\u20131619","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"131_CR10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","volume":"46","author":"SW Canna","year":"2014","unstructured":"Canna SW, Jesus AA de, Gouni S, Brooks SR, Marrero B, Liu Y et\u00a0al (2014) An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46(10):1140\u20131146","journal-title":"Nat Genet"},{"issue":"10","key":"131_CR11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ng.3066","volume":"46","author":"N Romberg","year":"2014","unstructured":"Romberg N, Al MK, Nelson-Williams C, Stiegler AL, Loring E, Choi M et al (2014) Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46(10):1135\u20131139","journal-title":"Nat Genet"},{"issue":"4","key":"131_CR12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0092-8674(00)80539-5","volume":"90","author":"The International FMF Consortium","year":"1997","unstructured":"The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797\u2013807","journal-title":"Cell"},{"issue":"23","key":"131_CR13","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"I Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, Royen-Kerkhoff A van et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J\u00a0Med 360(23):2426\u20132437","journal-title":"N Engl J\u00a0Med"},{"issue":"1","key":"131_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","volume":"97","author":"MF McDermott","year":"1999","unstructured":"McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et\u00a0al (1999) Germline mutations in the extracellular domains of the 55\u202fkDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97(1):133\u2013144","journal-title":"Cell"},{"issue":"7081","key":"131_CR15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237\u2013241","journal-title":"Nature"},{"issue":"2","key":"131_CR16","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"131_CR17","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, Y\u00fccel AE, Richard D, Murphy V et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064\u20133076","journal-title":"Arthritis Rheum"},{"issue":"2","key":"131_CR18","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De Meulemeester M, Pikhlak A, Y\u00fccel AE, Richard D, Murphy V et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"131_CR19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060\u20131068","journal-title":"Arthritis Rheum"},{"issue":"1","key":"131_CR20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/annrheumdis-2014-206074","volume":"75","author":"Y Wang","year":"2016","unstructured":"Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R (2016) AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis 75(1):286\u2013294","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"131_CR21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nm.3547","volume":"20","author":"C Schauer","year":"2014","unstructured":"Schauer C, Janko C, Munoz LE, Zhao Y, Kienhofer D, Frey B et\u00a0al (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 20(5):511\u2013517","journal-title":"Nat Med"},{"issue":"10","key":"131_CR22","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et\u00a0al (2015) 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789\u20131798","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"131_CR23","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","volume":"67","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et\u00a0al (2015) 2015 Gout Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 67(10):2557\u20132568","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"131_CR24","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/ard.2008.099713","volume":"68","author":"HK Choi","year":"2009","unstructured":"Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G et al (2009) Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 68(10):1609\u20131612","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"131_CR25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/art.21499","volume":"54","author":"J Graessler","year":"2006","unstructured":"Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Kuhlisch E et\u00a0al (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 54(1):292\u2013300","journal-title":"Arthritis Rheum"},{"issue":"6887","key":"131_CR26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH et\u00a0al (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417(6887):447\u2013452","journal-title":"Nature"},{"issue":"4","key":"131_CR27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","volume":"40","author":"V Vitart","year":"2008","unstructured":"Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN et\u00a0al (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40(4):437\u2013442","journal-title":"Nat Genet"},{"issue":"9654","key":"131_CR28","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","volume":"372","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372(9654):1953\u20131961","journal-title":"Lancet"},{"issue":"7639","key":"131_CR29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","volume":"336","author":"HK Choi","year":"2008","unstructured":"Choi HK, Curhan G (2008) Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336(7639):309\u2013312","journal-title":"BMJ"},{"issue":"11","key":"131_CR30","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-202732","volume":"72","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth N, House ME, Gamble GD, Horne A, Pool B, Purvis L et al (2013) Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis 72(11):1868\u20131873","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"131_CR31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semnephrol.2011.08.004","volume":"31","author":"YH Rho","year":"2011","unstructured":"Rho YH, Zhu Y, Choi HK (2011) The epidemiology of uric acid and fructose. Semin Nephrol 31(5):410\u2013419","journal-title":"Semin Nephrol"},{"key":"131_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207919","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C (2016) Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. doi:10.1136\/annrheumdis-2015-207919","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"131_CR33","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E et\u00a0al (2014) Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford) 53(12):2167\u20132174","journal-title":"Rheumatology (Oxford)"},{"key":"131_CR34","first-page":"123105","volume":"2014","author":"AK Tausche","year":"2014","unstructured":"Tausche AK, Reuss-Borst M, Koch U (2014) Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study. Int J\u00a0Rheumatol 2014:123105","journal-title":"Int J\u00a0Rheumatol"},{"issue":"23","key":"131_CR35","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA et\u00a0al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J\u00a0Med 353(23):2450\u20132461","journal-title":"N Engl J\u00a0Med"},{"issue":"11","key":"131_CR36","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr.","year":"2008","unstructured":"Schumacher HR Jr., Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540\u20131548","journal-title":"Arthritis Rheum"},{"issue":"2","key":"131_CR37","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"131_CR38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00296-013-2857-2","volume":"34","author":"AK Tausche","year":"2014","unstructured":"Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C et al (2014) As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 34(1):101\u2013109","journal-title":"Rheumatol Int"},{"issue":"7","key":"131_CR39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306(7):711\u2013720","journal-title":"JAMA"},{"issue":"9","key":"131_CR40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","volume":"72","author":"MA Becker","year":"2013","unstructured":"Becker MA, Baraf HS, Yood RA, Dillon A, Vazquez-Mellado J, Ottery FD et al (2013) Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 72(9):1469\u20131474","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"131_CR41","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HS Baraf","year":"2013","unstructured":"Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD et al (2013) Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 15(5):R137","journal-title":"Arthritis Res Ther"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-016-0131-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0131-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:13:13Z","timestamp":1568160793000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-016-0131-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1007\/s00393-016-0131-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}